Position in AKBA
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$96,955
-$401,114 QoQ
Shares Held
85,049
-53.4% QoQ
Ownership
0.031%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#69
of 170 holders
Holding Since
Sep 2020
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in AKBA Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026GSA CAPITAL PARTNERS LLP holds $11,914,926 across 21 Drug Manufacturers - Specialty & Generic names. AKBA ranks #18 (0.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INDV |
Indivior Pharmaceuticals, Inc.
|
55,201 | $2,264,897 | |
| 2 | ZTS |
Zoetis Inc.
|
18,470 | $1,327,254 | |
| 3 | IRWD |
Ironwood Pharmaceuticals Inc
|
259,512 | $1,092,545 | |
| 4 | BCRX |
Biocryst Pharmaceuticals Inc
|
90,210 | $902,100 | |
| 5 | LQDA |
Liquidia Corp
|
10,098 | $805,113 | |
| 6 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
11,219 | $717,455 | |
| 7 | AMLX |
Amylyx Pharmaceuticals, Inc.
|
39,241 | $704,768 | |
| 8 | XERS |
Xeris Biopharma Holdings, Inc.
|
82,830 | $656,013 |
All Filings in AKBA
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $96,955 | 85,049 | Shares | Sole | 2026-08-06 | |
| 2025-09-30 | $498,069 | 182,443 | Shares | Sole | 2025-11-07 | |
| 2022-09-30 | $153,755 | 486,568 | Shares | Sole | 2022-11-14 | |
| 2022-03-31 | $39,037 | 54,370 | Shares | Sole | 2022-05-11 | |
| 2021-09-30 | $732,602 | 254,376 | Shares | Sole | 2021-11-12 | |
| 2020-12-31 | $360,152 | 128,626 | Shares | Sole | 2021-02-03 | |
| 2020-09-30 | $225,054 | 89,663 | Shares | Sole | 2020-11-06 | |
| No filing history on record for this holder in this stock. | ||||||